Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBV Technologies (Nasdaq: DBVT) will participate in two investor events in March 2026: a fireside chat at Citizens Life Sciences Conference on March 10, 2026 at 1:40pm ET and one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026.
The Citizens presentation will be webcast live and a replay will be available on the company's Events page 90 days after the event.
DBVT (DBVT) reports the total number of shares and voting rights as of February 28, 2026 under Article 223-16 of the AMF General Regulations. The company lists 278,352,082 total shares and a total gross voting rights count of 278,352,082.
The total net voting rights (excluding shares without voting rights) is 278,236,200. Market: NYSE Euronext Paris. ISIN: FR0010417345.
DBV Technologies (Nasdaq:DBVT) reported additional positive data from the Phase 3 VITESSE study of the VIASKIN® Peanut Patch at AAAAI 2026. The trial met its primary endpoint: 46.6% responders on VIASKIN versus 14.8% on placebo (difference 31.8%, p<0.001).
Additional highlights: 82.8% increased eliciting dose by ≥1 step, 60.1% by ≥2 steps, low serious safety signals, and a planned Biologics License Application submission to FDA in H1 2026.
DBV Technologies (Nasdaq: DBVT) will present additional data from the positive VITESSE Phase 3 study of the VIASKIN Peanut Patch in children ages 4–7 at the AAAAI 2026 Annual Meeting in Philadelphia, Feb 27–Mar 2, 2026.
An oral abstract presentation is scheduled for Feb 28, 2:15–2:25pm ET, with a product theater on Feb 28, 10:00–10:30am ET featuring panelists discussing epicutaneous immunotherapy (EPIT) and early intervention. DBV will also exhibit at booth #1527.
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit in New York on February 12, 2026 at 2:30pm ET. A live webcast will be available and a replay will remain on the company site for 90 days.
Investors can access the live webcast via the company’s Events page and view the replay through the investor website.
DBVT (NYSE Euronext Paris) disclosed its total shares and voting rights as of January 31, 2026 under Article 223-16 of the AMF General Regulations.
The company reported 274,852,082 total shares and a gross total of 274,852,082 voting rights, with a net total of 274,792,237 voting rights (excluding shares without voting rights).
DBV Technologies (NASDAQ:DBVT) announced €166.7 million of gross proceeds from the full exercise of ABSA Warrants and BS Warrants issued in its March 2025 financing, resulting in issuance of 59,657,507 new shares and 71,005,656 second pre-funded warrants.
Proceeds, together with existing cash, are intended to fund working capital, preparation/submission of a potential BLA and launch readiness for VIASKIN Peanut in children 4–7 in the U.S., if approved. The company estimates these funds support operations for at least 12 months and sees no substantial doubt about going concern as of the press release date.
DBVT (NYSE Euronext Paris) reports the total number of shares and voting rights as of December 31, 2025. The company confirms 235,670,864 total shares and a total gross of voting rights: 235,670,864. The total net of voting rights (excluding shares without voting rights) is 235,596,284. This document supersedes the prior publication of January 5, 2026 to reflect earlier exercises of employee stock plan instruments and warrants from a previous financing.
DBV Technologies (Nasdaq: DBVT / Euronext: DBV) published its half-year report on the liquidity contract maintained with ODDO BHF, covering July 1, 2025 to December 31, 2025 and the contract inception on July 1, 2018.
As of December 31, 2025 the liquidity account held 74,580 shares and €527,891.63. At implementation on July 1, 2018 the account held 41,159 shares and €432,367.25. From Jul 1–Dec 31, 2025 the contract executed 1,658 buys and 1,867 sales, with traded volumes of 1,496,975 shares (€3,548,323.07) on purchases and 1,632,464 shares (€3,904,915.92) on sales.
DBVT (NYSE Euronext Paris, ISIN: FR0010417345) announced the total number of shares and voting rights as of December 31, 2025 in accordance with Article 223-16 of the AMF General Regulations.
The company reported a total number of shares of 232,207,589, a total gross of voting rights of 232,207,589, and a total net of voting rights of 232,133,009 (net excludes shares without voting rights). A PDF attachment is available for the detailed statement.